Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247672261> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4247672261 endingPage "208" @default.
- W4247672261 startingPage "205" @default.
- W4247672261 abstract "Platelets play a crucial role in the ischemic complications of percutaneous coronary procedures. The recent availability of C7E3 Fab (Abxiximab or ReoPro™), a chimeric monoclonal antibody Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor, has reduced abrupt closure and other adverse events and lessened the need for revascularization procedures. As the use for this drug has increased, rare cases of severe thrombocytopenia have been revealed. From August 1995 to June 1997, 452 patients at Charleston Area Medical Center who underwent percutaneous coronary revascularization procedures and were treated with abciximab were evaluated for the development of severe thrombocytopenia (i.e., platelet count less than 20,000 within 48 hr of treatment). A review of published reports of severe thrombocytopenia was also reviewed. A review of published reports of abciximab-induced severe thrombocytopenia, as well as our three cases, reveals that: 1) the incidence is less than 0.7%; 2) the nadir platelet count (range 1,000–16,000) was noted within 2–31 hr after abciximab infusion; 3) the platelet count increases to greater than 100,000 within 12 days in all patients; 4) bleeding episodes were treated with platelet transfusion with an improvement in platelet count within 24 hr in all patients in whom they were given; and 5) in the one patient treated with γ globulin alone, no significant rise in platelet count was noted. Acute severe thrombocytopenia can occur after ReoPro™ administration. Its development is not predictable and may occur within 2 hr of administration. Thrombocytopenia, therefore, requires consideration in every patient treated with this drug. It appears prudent to obtain a platelet count 2 hr after initiating ReoPro™. If thrombocytopenia develops, then the drug can be stopped in a timely manner and platelet transfusion can be given. Am. J. Hematol. 61:205–208, 1999. © 1999 Wiley-Liss, Inc." @default.
- W4247672261 created "2022-05-12" @default.
- W4247672261 creator A5003630612 @default.
- W4247672261 creator A5047078495 @default.
- W4247672261 creator A5051196178 @default.
- W4247672261 date "1999-07-01" @default.
- W4247672261 modified "2023-10-14" @default.
- W4247672261 title "Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy" @default.
- W4247672261 doi "https://doi.org/10.1002/(sici)1096-8652(199907)61:3<205::aid-ajh8>3.3.co;2-0" @default.
- W4247672261 hasPublicationYear "1999" @default.
- W4247672261 type Work @default.
- W4247672261 citedByCount "2" @default.
- W4247672261 crossrefType "journal-article" @default.
- W4247672261 hasAuthorship W4247672261A5003630612 @default.
- W4247672261 hasAuthorship W4247672261A5047078495 @default.
- W4247672261 hasAuthorship W4247672261A5051196178 @default.
- W4247672261 hasBestOaLocation W42476722611 @default.
- W4247672261 hasConcept C126322002 @default.
- W4247672261 hasConcept C141071460 @default.
- W4247672261 hasConcept C197934379 @default.
- W4247672261 hasConcept C2776335557 @default.
- W4247672261 hasConcept C2776689292 @default.
- W4247672261 hasConcept C2777871224 @default.
- W4247672261 hasConcept C2779464278 @default.
- W4247672261 hasConcept C2780400711 @default.
- W4247672261 hasConcept C500558357 @default.
- W4247672261 hasConcept C71924100 @default.
- W4247672261 hasConcept C89560881 @default.
- W4247672261 hasConceptScore W4247672261C126322002 @default.
- W4247672261 hasConceptScore W4247672261C141071460 @default.
- W4247672261 hasConceptScore W4247672261C197934379 @default.
- W4247672261 hasConceptScore W4247672261C2776335557 @default.
- W4247672261 hasConceptScore W4247672261C2776689292 @default.
- W4247672261 hasConceptScore W4247672261C2777871224 @default.
- W4247672261 hasConceptScore W4247672261C2779464278 @default.
- W4247672261 hasConceptScore W4247672261C2780400711 @default.
- W4247672261 hasConceptScore W4247672261C500558357 @default.
- W4247672261 hasConceptScore W4247672261C71924100 @default.
- W4247672261 hasConceptScore W4247672261C89560881 @default.
- W4247672261 hasIssue "3" @default.
- W4247672261 hasLocation W42476722611 @default.
- W4247672261 hasOpenAccess W4247672261 @default.
- W4247672261 hasPrimaryLocation W42476722611 @default.
- W4247672261 hasRelatedWork W1581646450 @default.
- W4247672261 hasRelatedWork W1981408803 @default.
- W4247672261 hasRelatedWork W1982332538 @default.
- W4247672261 hasRelatedWork W2008337977 @default.
- W4247672261 hasRelatedWork W2032341728 @default.
- W4247672261 hasRelatedWork W2077772721 @default.
- W4247672261 hasRelatedWork W2127449094 @default.
- W4247672261 hasRelatedWork W2414275444 @default.
- W4247672261 hasRelatedWork W2416889669 @default.
- W4247672261 hasRelatedWork W2466093593 @default.
- W4247672261 hasVolume "61" @default.
- W4247672261 isParatext "false" @default.
- W4247672261 isRetracted "false" @default.
- W4247672261 workType "article" @default.